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Key questions
What is already known about this subject?
 ► Tobacco smoking is the number one risk factor for 
lung cancer and is linked to 80%–90% of these 
cancers.
 ► Studies have indicated the mutation burden asso-
ciated with smoking predicts response to immuno-
therapy. This is due to a higher programmed death 
ligand 1 (PD-L1) tumour proportion score (TPS) 
among smokers.
What does this study add?
 ► There is a better overall response rate among the 
current/former smoker group than the no smoker 
group when treated with immunotherapies. So also 
in patients having a molecular ‘smoking signature’. 
This is due to a higher PD-L1 TPS and probably a 
higher mutational burden due to smoking.
 ► The situation seems to be different during therapy. 
The KEYNOTE-024 documented pembrolizumab 
being more effective among former smokers than 
among current smokers.
How might this impact on clinical practice?
 ► Clinicians may encourage patients undergoing im-
munotherapy to quit smoking to achieve a better 
outcome.
 ► There is a need to clarify the benefit achieved. 
When elucidated, more pressure can be put on pa-
tients continuing smoking during therapy. They may 
cause waste of healthcare resources spent on their 
therapy.
AbstrAct
Background Programmed death ligand 1 (PD-L1) 
targeting immunotherapies, as pembrolizumab and 
nivolumab, have significantly improved outcome in 
patients with non-small cell lung cancer (NSCLC). Tobacco 
smoking is the number one risk factor for lung cancer 
and is linked to 80%–90% of these cancers. Smoking 
during cancer therapy may influence on radiotherapy 
and chemotherapy outcome. We aimed to review the 
knowledge in immunotherapy.
Patients and methods A systematic review was done. 
We searched for documents and articles published in 
English language and registered in Cochrane Library, 
National Health Service (NHS) Centre for Reviews 
and Dissemination (CRD), Embase or Medline. The 
search terms were (A) (Lung cancer or NSCLC) with 
(pembrolizumab or nivolumab) with PD-L1 with (tobacco 
or smoking) and (B) Lung Neoplasms and Immunotherapy 
and (smoking cessation or patient compliance). 68 papers 
were detected and two more were added during review 
process (references) and six based on information from the 
manufacturers.
Results Nine papers were selected. High PD-L1 
expression (≥50%) was correlated with current/ever 
smoking history in three studies. Six studies revealed a 
higher overall response rate (ORR) among current/former 
smokers. The ORR was generally (six studies) better 
among the current/former smoker group. So also when 
tumours had a molecular ‘smoking signature’ (one study). 
This was probably due to a higher mutational burden. In 
two studies, minor or no difference was revealed.
One study (KEYNOTE-024) compared former and current 
smokers, and documented pembrolizumab being more 
effective among former smokers than current smokers.
Conclusions Tobacco smoking patients with NSCLC 
generally have a higher PD-L1 tumour proportion score 
and experience a better ORR of immunotherapy than no 
smokers. There is little evidence on the effect of smoking 
during immunotherapy, but one study (KEYNOTE-024) may 
indicate survival gains of smoking cessation.
IntRoduCtIon
Cigarette smoking is the number one risk 
factor for lung cancer and is linked to about 
80%–90% of lung cancers.1 There are more 
than 4000 chemical constitutes of ciga-
rette smoke and there are several potential 
carcinogens, including polycyclic aromatic 
hydrocarbons, aromatic amines, nitrosamines 
and other organic and inorganic compounds, 
such as benzene, vinyl chloride, arsenic and 
chromium. The carcinogens are associated 
with DNA mutations. Lung cancer accounts 
for 21% of the total cancer deaths world-
wide.1 Every year, 1.8 million people are 
diagnosed with lung cancer, and 1.6 million 
people die because of the disease. In the 
USA, lung cancer represents almost 27% of 
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all cancer deaths.2 Five-year survival rates vary from 4% to 
17%, depending on stage and regional differences.3
Rates have been declining due to the reduced prevalence 
of smoking. However, in the USA, 18% of adults still smoke 
cigarettes.2 4 A similar figure (19%) has been reported in 
Norway.5 The declining rates have, however, been absent in 
several economically low/middle-income countries.1
Today, lung cancer from smoking is, to a great extent, 
a preventable disease.6 A 62% reduction in lung cancer 
mortality has been reported in association with smoking 
cessation at age 50.7 Quitting smoking decreases the risk 
of dying from lung cancer and from other tobacco-re-
lated illnesses. Consequently, programmes and policies 
that can decrease the numbers of tobacco smokers will 
have significant impact on patients’ quality of life and 
healthcare budgets.7
During the last years, new costly drugs have been intro-
duced for the treatment of lung cancer.8 Examples of 
inhibitory signalling agents approved by the Food and 
Drug Administration include antibodies targeting cyto-
toxic T-lymphocyte-associated protein 4 and programmed 
death 1 (PD-1)/PD-ligand 1 (L1) receptors.9 Especially, 
PD-1/PD-L1 blockage therapy has shown activity in lung 
cancer.10–12 Economic resources spent on costly new thera-
pies could be allocated to preventive strategies. Treatment 
effects in various subgroups should therefore be monitored.
Smoking can cause lung cancer and then block the 
body from fighting it by weakening the immune system.13 
Tobacco smoking during immunotherapy may influence 
on treatment outcome. Progression-free survival (PFS) 
has been documented varying, depending on whether 
the patient was a former or current smoker.14 Further-
more, the mutation burden associated with smoking may 
predict response to anti-PD-1 therapy.15 In this review, we 
aimed to clarify the consequences of tobacco smoking 
before and during immunotherapy.
MateRIals and MetHods
We performed a systematic literature search for studies 
on immunotherapies in lung cancer and possible effects 
of tobacco smoking. In February 2018, we searched for 
documents and articles published in English language. 
The following databases were used: Cochrane Library, 
National Health Service (NHS) Centre for Reviews 
and Dissemination (CRD), Embase and Medline. The 
following search terms were used: (A) (Lung cancer or 
NSCLC) with (pembrolizumab or nivolumab) with PD-L1 
with (tobacco or smoking) and (B) Lung Neoplasms 
and Immunotherapy and (smoking cessation or patient 
compliance). A total of 68 papers were detected.
Initially, we screened all titles and abstracts of the arti-
cles. The selected papers were investigated and studies 
reporting any analysis on correlation between smoking 
and immunotherapy were selected (n=7). Furthermore, 
the references of the selected papers were screened and 
another two articles were added.14 16
Merck Sharp & Dohme, the manufacturer of 
pembrolizumab (Keytruda), Bristol Myers Squibb, the 
manufacturer of nivolumab (Opdivo), and Roche, 
the manufacturer of atezolizumab (Tecentriq) were 
contacted and requested for information concerning 
tobacco smoking and the treatment of non-small cell lung 
cancer (NSCLC) using pembrolizumab, nivolumab or 
atezolizumab. They confirmed several of the selected arti-
cles, and two more articles and four abstracts were added 
for further analyses.17–22
Because of low level of evidence, abstracts only, book 
chapters, errata, editorial comments and letters to the 
editor were not included. Consequently, six papers 
(published as abstracts only) were excluded. Further-
more, articles were excluded when they did not focus on 
lung cancer, immunotherapy or the use of tobacco, and/
or not written in English language (61 articles rejected). 
We reviewed the full text of all articles twice to confirm 
their eligibility. Following the selection process, nine arti-
cles were included into the final study.14–18 23–26 Data were 
extracted from the selected papers employing Microsoft 
Excel V.2016 for the database. Never smoking was defined 
as patients who had smoked less than 100 cigarettes in 
their lifetime or ≤10 package-years.24 26 Study character-




The literature selection process revealed nine studies 
fulfilling the inclusion criteria and reporting data on 
tobacco use, PD-L1 expression and response on immu-
notherapy in NSCLC. The selection process and key find-
ings are shown in figure 1 and table 1.
smoking before immunotherapy
Smoking history and its influence on the effect of immu-
notherapy was somewhat diverging. In three studies, high 
PD-L1 expression (≥50%) was correlated with current/
ever smoking history.24–26 Gainor et al documented in 
their retrospective study (58 patients) a better (but not 
significant, p=0.123) overall response rate (ORR) among 
heavy smokers versus never or light smokers.24 The figures 
were 20.6% and 4.2%, respectively. Garon and colleagues 
published, on behalf of the KEYNOTE-001 investigators, 
that current or former smoking status was associated with 
an increased response to treatment.16 They concluded this 
finding was probably due to a higher mutational burden 
among these patients. The median PFS among current/
former smokers was 4.2 months vs 2.1 months among the 
never smokers. The corresponding overall survival (OS) 
figures were 14.3 and 8.8 months, respectively.
Gandhi and associates added pembrolizumab or 
placebo to pemetrexed and a platinum-based regimen in 
first-line therapy of patients with advanced NSCLC.17 Most 
patients (88.1%) were former or current smokers. They 
revealed an HR for OS of 0.23 (95% CI 0.10 to 0.54) for 
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Table 1 An overview of the study characteristics, treatment and comparator, type of evaluation, perspective, year of value 
and time horizon of the selected studies
Reference Study characteristics
Treatment and 
comparator n Key findings




50 Response to treatment before nivolumab 
associated with response to nivolumab. 
Smoking history had no significant influence 
(never vs current/former smoker ORR 5% vs 
26%, p=0.1269).
16 Sequenced exons of NSCLCs Pembrolizumab 34 Efficacy greater in tumours harbouring 
smoking signature (ORR 56% vs 17%, 
p=0.03)
25 EGFR and ALK rearrangements 
in NSCLC
PD-1/PD-L1 inhibitors 58 Smoking history had no significant influence 
(never/light vs heavy smokers ORR 4.2% vs 
20.6%, p=0.123).
26 Adenocarcinoma of the lung Testing PD-L1 tumour 
proportion score
71 Tumours with a PD-L1 TPS>50% were 
significantly associated with smoking status.
27 Patients with NSCLC in East 
Asia. 108 SCC and 221 LUAD.
PD-L1 expression/
distribution
329 TPS>50% correlated with smoking history 
in both SCC (p=0.008) and adenocarcinoma 
(p=0.002).
17 Pembrolizumab in NSCLC. 
KEYNOTE-001.
Pembrolizumab10 mg/
kg every 2 weeks, 2 
mg/kg every 3 weeks, 
10 mg/kg every 3 
weeks
495 Current/former smoking status was 
associated with increased ORR (10.3% vs 
22.5% in never smokers).
15 Pembrolizumab or platinum-
based CT. KEYNOTE-024.
Pembrolizumab 200 mg 
every 3 weeks
Platinum
305 ORR 44.8% vs 27.8%. HR for progression/
death among smokers 0.68 and former 
smokers 0.47.
18 Pemetrexed and platinum 
plus pembrolizumab or 
placebo in advanced NSCLC. 
KEYNOTE-189.
Pemetrexed, platinum 
and pembrolizumab or 
placebo every 3 weeks
616 88.1% current or former smokers. HR for 
death among current or former smokers 0.54 
versus never smoker 0.23. Progression-free 
survival HR 0.54 and 0.43, respectively.
19 Nivolumab versus docetaxel in 
patients with NSCLC. Phase III 
study.
Nivolumab 3 mg/kg 
every 2 weeks versus 
docetaxel 75 mg/m2 
every 3 weeks
582 79% were current/former smokers. HR was 
0.70 and 1.02 in former/current smokers and 
never smokers, respectively.
ALK, anaplastic lymphoma receptor tyrosine kinase; CT, chemotherapy; EGFR, epidermal growth factor receptor; LUAD, lung 
adenocarcinoma; NSCLC, non-small cell lung cancer; ORR, overall response rate; PD-L1, programmed death ligand 1; SCC, squamous cell 
carcinoma; TPS, tumour proportion score.
never smokers and 0.54 (95% CI 0.41 to 0.71) for current/
former smokers. The corresponding figures for disease 
progression or death were 0.43 (95% CI 0.23 to 0.81) and 
0.54 (95% CI 0.43 to 0.66), respectively. However, there 
were only 73 never smokers among 616 patients, causing 
a wide CI. The data cut-off was 8 November 2017.
Borghaei and colleagues compared nivolumab and 
docetaxel in 582 patients with advanced non-squa-
mous NSCLC and concluded an OS benefit in favour of 
nivolumab (12.2 months vs 9.4 months).18 A total of 79% 
were current or former smokers. When comparing OS 
between current/former smokers versus never smoked, 
they revealed smokers having a greater benefit of 
nivolumab therapy. The unstratified HRs (95% CI) were 
0.70 (95% CI 0.56 to 0.86) vs 1.02 (95% CI 0.64 to 1.61), 
respectively. However, the interpretation of the results 
was somewhat limited by the wide CI in a small subgroup 
of patients (118 out of 582 had never smoked).
Based on the majority of studies, we concluded, there is 
a correlation between smoking history and higher PD-L1 
tumour proportion score.16 18 25 26
Molecular signature of smoking and immunotherapy
Rizvi and colleagues identified the molecular signature 
of smoking to clarify the efficacy of pembrolizumab in 
patients with NSCLCs harbouring the smoking signa-
ture.15 A previously validated binary classifier was 
applied.27 The ORR was significantly higher in tumours 
with smoking signature versus never smoking signature 
(56% vs 17%, p=0.03).15 Similar findings were detected in 
PFS with median survival not reached versus 3.5 months 
(p=0.0001). Whereas smoking signature significantly 
correlated with efficacy, self-reported smoking status 
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Figure 1 The selection process.
did not. Kobayashi et al did also conclude similarly.23 In 
their study, smoking history (never vs current or former 
smoker) did not influence on response rate of nivolumab 
monotherapy, but the study included only 50 patients and 
31 out of them were current smoker or ever smoker.
smoking during immunotherapy
There was only one study comparing former smokers 
with current smokers.14 The categorisation was based 
on patients’ smoking status at study entry and the inves-
tigators documented a better effect of pembrolizumab 
therapy among former smokers (216 patients) compared 
with current smokers (65 patients). The HRs for disease 
progression or death were for current smokers 0.68 (95% 
CI 0.17 to 0.71) and for former smokers 0.47 (95% CI 0.33 
to 0.67). Brahmer et al updated these data (data cut-off 10 
July 2017) in an abstract version.28 The paper indicated 
a better response among those being former smokers 
at the initiation of immunotherapy. No study compared 
smoking habits in terms of whether the patient actually 
stopped smoking or continued during immunotherapy.
dIsCussIon
We conclude most studies revealed a correlation between 
tobacco smoking and higher PD-L1 tumour proportion 
score. This was probably due to a higher mutational 
burden. There was little evidence on the effect of tobacco 
smoking during immunotherapy. However, one major 
study revealed better outcome for former smokers than 
for the current ones.14 This indicates that smoking cessa-
tion should be encouraged before and during immuno-
therapy.
smoking status, response rate and survival
Some discrepancy between studies may be due to various 
numbers of patients and the fact that smoking status 
was based on patients’ self-reports.15 23 24 There were no 
follow-ups and none of the studies did actually measure 
blood level of nicotine and no studies did split data 
between former and current smokers.29 Consequently, 
there is a need for studies on the possible effect of contin-
uing smoking during immunotherapy.
Smoking status among patients with NSCLC has been 
reported varying between real world and clinical trials.30 
However, we could not confirm this statement. Khozin 
et al mentioned a real-world current/former smoker 
figure (88%) similar to that of the KEYNOTE-024 study 
(92%).14 30 Similar figures have also been reported by 
others (79%–88%).17 18
The proportion score of PD-L1 expression of at least 
50% was associated with a higher ORR, and longer PFS 
and OS.31 This effect was hypothesised to be due to a 
higher mutational burden.32–34 Consequently, differences 
in ORR between various studies might be due to varia-
tions in the percentage of smokers. This was also argued 
by Kobayashi et al.23
In our review, most data were on pembrolizumab and 
nivolumab. However, other drugs have also been tested 
and data published in abstract forms. Such an example 
is the MPDL3280A.35 This is an engineered IgG anti-
PD-L1 antibody with modified Fc domain that prevents 
antibody-dependent cell-mediated cytotoxicity in other 
immune cells expressing PD-L1. The MPDL3280A 
achieved a better ORR among former and current 
smokers (25%) than among never smokers (16%).35 This 
was also confirmed by others.36
Pneumonitis is one of the potentially serious side effects 
of immunotherapy. Ahn and colleagues reported pneu-
monitis grades 3–5 in 3.8% of patients with NSCLC under-
going pembrolizumab therapy.37 Smoking history did 
however not influence the risk of pneumonitis. Leighl et 
al recently published an abstract updating the KEYNOTE-
001 study.19 Three years of survival in previously treated 
patients was better among ever (21.9%; 95% CI 17.1 to 
27.2) than never (11.9%; 95% CI 6.3 to 19.5) smokers. 
Looking at treatment-naïve patients, the 3 years of OS was 
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in favour of those who had never smoked (24.0%; 95% CI 
11.7 to 38.7 vs 45.5%; 95% CI 16.7 to 70.7). Consequently, 
the never smoked group seems to have the best prognosis 
in the treatment-naïve setting. However, the number of 
patients and the number of adverse events were too small 
to draw any conclusions.
Molecular signature and immunotherapy
Rizvi and colleagues employed a previously validated 
binary classifier to identify the molecular signature of 
smoking.15 27 The classifier applied differentiated trans-
version-high (smoking signature) from transversion-low 
(never smoking signature) tumours.27 This classification 
was based on the fact that past or present smoking has 
been shown to be associated with cytosine to adenine 
(C>A) nucleotide transversions both in individual genes 
and genomic-wide.38 Furthermore, the C>A nucleotide 
transversion has been shown inversely correlated with 
cytosine to thymidine (C>T) transition frequency.38 39
It could be questioned whether smoker tumours should 
be defined by the genetic signature rather than by self-re-
ported smoking status. However, we did not reveal large-
scale studies that could answer this question and the study 
by Rizvi et al did only include 30 patients.15
On the other hand, we revealed one study showing a 
correlation between amounts of smoking and genetic 
alterations.40 The puff volume was indicated a more 
powerful objective phenotype of smoking behaviour than 
self-reported cigarettes per day and nicotine dependence.
should patients quit smoking during immunotherapy?
Patients frequently ask what they can do themselves to 
improve treatment outcome. Smoking cessation may be 
a key action in this setting.41 Smoking not only causes 
cancer, but continued smoking may alter cancer biology, 
leading to tumours that are resistant to treatment and 
thereby increase mortality.42 Smoking cessation may also 
improve cardiovascular status. Consequently, we argue 
that oncologists and pulmonologists should encourage 
smoking cessation during immunotherapy.
O’Malley and colleagues did a review of the literature 
on metabolism and effectiveness of systemic therapy for 
lung cancer.43 They revealed that smokers might exhibit a 
more rapid clearance, requiring a higher dose compared 
with non-smokers. However, no studies have shown the 
influence of continuous smoking on the clearance of 
immunotherapies. A detailed smoking history should 
be part of future clinical evaluations in NSCLC. At least 
three levels of smoking status should be ascertained 
(never smoker, former smoker and current smoker) and 
the number of pack-years should be calculated.
Smoking cessation is not easy and the success rate has 
been disappointing.44 Therefore, patients should be 
offered assistance during and after smoking cessation.45
ConClusIon
Tobacco smoking patients with NSCLC generally 
have a higher PD-L1 tumour proportion score and 
experience a higher response rate in immunotherapy 
than non-smokers. There is little evidence on the effect of 
smoking during immunotherapy, but one study indicates 
better outcome for former smokers than for the current 
ones. Further studies are necessary to elucidate the nega-
tive effects of smoking during immunotherapy.
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